■ 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 本公告所载2025年度主要财务数据为初步核算数据，未经会计师事务所审计，具体数据以江苏吉贝尔药 业股份有限公司（以下简称"公司"）2025年年度报告为准，提请投资者注意投资风险。 一、2025年度主要财务数据和指标 单位：人民币；元 注：1.本报告期指2025年1月1日至2025年12月31日，期初数同法定披露的上年年末数。 2.以上财务数据及指标以合并报表数据填列，但本报告期数据未经审计，最终结果以公司2025年年度报 告为准。 二、经营业绩和财务状况情况说明 公司不存在影响本次业绩快报内容准确性的重大不确定性因素。本公告所载2025年度主要财务数据为初 步核算数据，未经会计师事务所审计，具体数据以公司2025年年度报告为准，提请投资者注意投资风 险。 特此公告。 江苏吉贝尔药业股份有限公司董事会 2026年2月28日 报告期内，公司实现营业总收入964,930,489.25元，同比增加7.63%；归属于母公司所有者的净利润 258,668,187.82元，同比增加17. ...

报告期内，公司整体经营情况良好。一方面，持续强化团队建设和市场开发，营业总收入、归属于母公 司所有者的净利润均实现了增长，其中主要产品尼群洛尔片销售收入保持了较快的增长态势；另一方 面，积极推进抗抑郁新药JJH201501、抗肿瘤新药JJH201601等新药的研发进程，顺利完成抗抑郁新药 JJH201501III期临床试验，有序推进抗肿瘤新药JJH201601IIa期临床试验。同时，为了进一步建立、健 全公司长效激励机制，公司制定并实施2025年限制性股票激励计划，报告期股份支付费用为2,350.64万 元（未经审计，最终数据以经审计的年度报告为准）。 格隆汇2月27日丨吉贝尔(688566.SH)公布2025年度业绩快报，报告期内，公司实现营业总收入9.65亿 元，同比增加7.63%；归属于母公司所有者的净利润2.59亿元，同比增加17.94%。 ...

证券日报网讯 2月27日，吉贝尔发布公告称，公司2025年实现营业总收入964930489.25元，同比增加 7.63%；归属于母公司所有者的净利润258668187.82元，同比增加17.94%。 （文章来源：证券日报） ...

每经头条（nbdtoutiao）——中美大反转，中国AI调用量首超美国，A股嗨了，多板块掀涨停潮！华尔 街知名分析师：中国算力路径颠覆传统认知 每经AI快讯，吉贝尔2月27日晚间发布2025年度业绩快报，营业收入约9.65亿元，同比增加7.63%；归属 于上市公司股东的净利润约2.59亿元，同比增加17.94%；基本每股收益1.3元，同比增加15.04%。 （记者 曾健辉） ...

归属于母公司所有 者的每股净资产 本公告所载 2025 年度主要财务数据为初步核算数据，未经会计师事务所审 计，具体数据以江苏吉贝尔药业股份有限公司（以下简称"公司"）2025 年年度 报告为准，提请投资者注意投资风险。 一、2025 年度主要财务数据和指标 | 项目 | 本报告期 | 上年同期 | 增减变动幅 | | --- | --- | --- | --- | | | | | 度（％） | | 营业总收入 | 964,930,489.25 | 896,534,453.46 | 7.63 | | 营业利润 | 252,760,302.64 | 254,661,090.24 | -0.75 | | 利润总额 | 298,213,562.36 | 253,361,570.76 | 17.70 | | 归属于母公司所有 | 258,668,187.82 | 219,327,779.08 | 17.94 | | 者的净利润 | | | | | 归属于母公司所有 者的扣除非经常性 | 216,002,270.71 | 215,090,754.66 | 0.42 | | 损益的净利润 | | | | | 基本每股收益 ...

吉贝尔发布业绩快报，2025年度实现营业总收入9.65亿元，同比增长7.63%；净利润2.59亿元，同比增 长17.94%。报告期内，公司整体经营情况良好。一方面，持续强化团队建设和市场开发，营业总收 入、归属于母公司所有者的净利润均实现了增长，其中主要产品尼群洛尔片销售收入保持了较快的增长 态势；另一方面，积极推进抗抑郁新药JJH201501、抗肿瘤新药JJH201601等新药的研发进程，顺利完成 抗抑郁新药JJH201501 III期临床试验，有序推进抗肿瘤新药JJH201601 IIa期临床试验。 ...

中国质量新闻网讯 据山东省青岛市市场监督管理局网站消息，近日，青岛市市场监督管理局发布关于对青岛吉贝尔电器股份有限公司等1753家公司拟强制 注销的公告。 青岛吉贝尔电器股份有限公司等1753家公司: 青岛吉贝尔电器股份有限公司等1753家公司被吊销营业执照、责令关闭或者被撤销之日已满三年，且未向企业登记机关申请注销公司登记。根据《中华人民 共和国公司法》第二百四十一条和《市场监督管理强制注销公司登记制度实施办法》规定，现拟予以强制注销公司登记。 现已对1753家公司发起拟强制注销公告。2026年5月4日前，相关部门、债权人以及其他利害关系人对拟强制注销公司登记有异议的，可通过国家企业信用信 息公示系统或者以书面形式向青岛市市场监督管理局提出。 联系电话：85730850 青岛市市场监督管理局 2026年2月25日 青岛市市场监督管理局关于对青岛吉贝尔电器股份有限公司等1753家公司拟强制注销的公告 ...

证券日报网讯 2月25日，吉贝尔在互动平台回答投资者提问时表示，截至2026年2月13日收市，公司股 东总数为8195户。 （文章来源：证券日报） ...

Core Viewpoint - The article discusses the current funding logic in the market, highlighting the significant movements of public funds in the technology sector, particularly in the semiconductor and biopharmaceutical industries, as they adjust their portfolios based on performance and valuation metrics [3][8]. Group 1: Public Fund Movements - Public funds have shown a notable shift in their holdings, particularly in the STAR Market, with the STAR 50 Index rising by 12.1% this year [3][4]. - The total market capitalization of STAR Market companies reached 10.4 trillion yuan, with the technology sector dominating, accounting for 62.1% of the total market cap [5][6]. - The semiconductor industry remains the core focus for fund allocation, with 12 companies in the sector having a market capitalization exceeding 10 billion yuan [9][11]. Group 2: Semiconductor Sector Insights - The market's pricing anchor for the semiconductor sector has shifted from "valuation expansion" to "performance realization," emphasizing the importance of actual earnings [13][14]. - Key drivers for future growth in the semiconductor sector include strong order backlogs, profit growth through acquisitions and expansions, and sustained price increases in advanced processes [13][14]. - Public funds have significantly increased their holdings in semiconductor materials, chip design, and equipment, with companies like ShenGong Co. seeing an 11% increase in fund holdings [15][21]. Group 3: Biopharmaceutical Sector Insights - The biopharmaceutical sector is a critical area for public funds, with major holdings in companies like BeiGene and United Imaging Healthcare, although the sector has faced a reduction in holdings for several key companies [24][26]. - The article notes that innovative drug companies are currently under pressure, with significant reductions in holdings observed in companies like BaiLi TianHeng and RongChang Biopharma [26][28]. - Despite the challenges, companies with strong earnings potential and innovative drug pipelines are still attracting interest from public funds, indicating a selective investment approach [35][40].

Core Viewpoint - The company has experienced a slight increase in shareholder numbers and net capital inflow, with stock performance slightly outperforming its industry sector [1][2]. Recent Events - As of February 10, 2026, the total number of shareholders for the company reached 7,927, an increase of 8 shareholders, representing a growth of 0.10%. The average market value per shareholder rose to 725,100 yuan. On February 11, the company reported a net capital inflow of 5.64 million yuan, accounting for 12.07% of the total trading volume, with the stock price increasing by 0.38% on that day. Additionally, the financing balance reached 226 million yuan on February 12, with a financing purchase amount of 11.91 million yuan, indicating an increase in market activity [2]. Stock Performance - Over the past 7 days, the company's stock price has increased by 1.68%, with a high of 29.16 yuan and a low of 28.49 yuan, resulting in a price fluctuation of 2.35%. The latest closing price on February 13 was 29.04 yuan, with a single-day increase of 0.41% and a trading volume of 6.81 million yuan, leading to a turnover rate of 0.12%. During the same period, the overall pharmaceutical and biological sector experienced a slight decline of 0.18%, while the chemical pharmaceutical sector rose by 0.07%, indicating the company's performance was slightly better than its industry [3]. Financial Report Analysis - According to the company's Q3 2025 report, the revenue for the first three quarters was 704 million yuan, reflecting a year-on-year growth of 9.52%. The net profit attributable to shareholders was 197 million yuan, with a year-on-year increase of 12.8%. However, the non-recurring net profit for Q3 alone was 46.81 million yuan, showing a year-on-year decline of 7.98%, which raises concerns about the sustainability of profitability. The gross margin remained high at 89.69%, and the debt ratio was 10.22%, indicating a relatively stable financial structure [4]. Institutional Viewpoints - According to Guosen Securities' investment strategy for the pharmaceutical and biological industry in February 2026, the valuation of the medical services and consumer sectors is at historical lows, with expectations for fundamental recovery in 2026. The report suggests focusing on undervalued stocks with improving performance. Although the report does not directly mention the company, it highlights opportunities within the chemical pharmaceutical sector, which is relevant to the company's main business [5].